Atjaunināt sīkdatņu piekrišanu

CPP, Cell-Penetrating Peptides Second Edition 2023 [Mīkstie vāki]

  • Formāts: Paperback / softback, 556 pages, height x width: 279x210 mm, 19 Illustrations, color; 7 Illustrations, black and white; XXI, 556 p. 26 illus., 19 illus. in color., 1 Paperback / softback
  • Izdošanas datums: 19-Oct-2024
  • Izdevniecība: Springer International Publishing AG
  • ISBN-10: 3031387333
  • ISBN-13: 9783031387333
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 145,08 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Standarta cena: 170,69 €
  • Ietaupiet 15%
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 556 pages, height x width: 279x210 mm, 19 Illustrations, color; 7 Illustrations, black and white; XXI, 556 p. 26 illus., 19 illus. in color., 1 Paperback / softback
  • Izdošanas datums: 19-Oct-2024
  • Izdevniecība: Springer International Publishing AG
  • ISBN-10: 3031387333
  • ISBN-13: 9783031387333
Citas grāmatas par šo tēmu:
In this book, a summary and update of the most important areas of cell-penetrating peptides (CPP) research are presented, while raising relevant questions for further development. The CPP sequences are presented and discussed throughout the book. The methods for testing CPP mechanisms are discussed in detail. Various approaches for the testing of endocytotic pathways of CPP uptake are also described. Different CPP uptake experiments are compared since it is becoming clear that it is often best to apply several methods in a complementary manner in order to most comprehensively evaluate CPP uptake mechanisms due to the complexity of these processes. A brief summary of functionality issues of CPPs, both in vitro and in vivo, is discussed. Therapeutic potential of CPPs and commercial developments are discussed.





The present, second edition of this book is the updated and expanded version of the first edition, published in 2019. The development of the field of cell-penetrating peptides in these five years has been obvious and exciting.





This second edition of the book has been partly reorganized and comprehensively expanded with the exciting research in 2019-2023. Around 2500 novel scientific articles have become available, most of them are reviewed in the second edition. Additional rapidly growing areas of high impact presented in this second edition are therapeutic developments (Chapter 16) and delivery of oligonucleotides and proteins/peptides (Chapters 5 and 6) including novel reports on genome editing with CPP assistance. Also, several additional examples are available now on clinical trials using CPPs (Chapter 15).





The book is written for researchers and students in the field.
1. Introduction.- 2. Classes and applications of CPP.-
3. CPP selection,
prediction and in silico analysis.-
4. Labeling of CPPs.-
5. Methods for CPP
functionalization with oligonucleotides.-
6. Additional (gene therapeutic)
platforms.-
7. Protein delivery and mimicry.-
8. General targeting
strategies.-
9. Targeting specific barriers.-
10. Methods for molecular
imaging, detection and visualization of CPPs.-
11. Methods for structural
studies of CPPs.-
12. Kinetics.-
13. Toxicity and immune response.-
14.
Cell-translocation mechanisms of CPPs.-
15. Clinical trials and
commercialization using CPPs.-
16. Therapeutic potential of CPPs.-
17. CPP
functionalized nanoparticles.-
18. Concluding remarks.
Ülo Langel is a Professor Emeritus at the Department of Biochemistry and Biophysics, Stockholm University, and at the Institute of Technology, Tartu University. Prof. Langel graduated from Tartu University, Tartu, Estonia, as bioorganic chemist in 1974; he has received his PhD degree twice: in 1980 from Tartu University, Tartu, Estonia (bioorganic chemistry), and in 1993 from Tartu University/Stockholm University (biochemistry/neurochemistry). His professional experience includes a career at Tartu University, Tartu, Estonia (from junior research fellow to Associate Professor, Visiting Professor, and Professor 1974-now); The Scripps Research Institute, La Jolla, CA, USA (Associate Professor, and Adjunct Professor 2000-now); and Stockholm University (from research fellow to Associate Professor, Professor and Chairman, 1987-now). He is a Honorary Professor at Ljubljana University, Slovenia. He was a Chairman of the Board of small companies Pepfex (Stockholm) and Cepep (Estonia) and member of the Board of Orexo (Sweden). In 2013 he was elected a member of Academia Europaea and in 2015, a foreign member of the Estonian Academy of Sciences.





 





Prof. Langel has been selected as a Fellow Member of International Neuropeptide Society (1995), and is a member of International Society for Neurochemistry, European Peptide Society, Swedish Biochemical Society and Estonian Biochemical Society.  He has been awarded a White Star Order, 4th class, by Estonian Republic. He has been invited lecturer at numerous international conferences, and is a coauthor of more than 480 scientific articles and 20 approved or pending patents. His research interest is in neurochemistry where his research is aimed to study peptides, particularly neuropeptide receptors, and in drug delivery by cell-penetrating peptides